Wedbush reiterated their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a research note released on Wednesday morning. Wedbush also issued estimates for Albireo Pharma’s FY2022 earnings at $7.44 EPS.
“Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders.”,” the firm’s analyst wrote.
Several other brokerages also recently issued reports on ALBO. Zacks Investment Research downgraded shares of Albireo Pharma from a buy rating to a hold rating in a report on Monday, November 13th. Needham & Company LLC reissued a buy rating on shares of Albireo Pharma in a report on Thursday, October 26th. Cowen reissued a buy rating on shares of Albireo Pharma in a report on Friday, November 17th. Roth Capital began coverage on shares of Albireo Pharma in a report on Wednesday, November 15th. They set a buy rating and a $92.00 price target for the company. Finally, ValuEngine downgraded shares of Albireo Pharma from a hold rating to a sell rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Albireo Pharma presently has an average rating of Buy and a consensus target price of $53.75.
In related news, major shareholder Plc Astrazeneca sold 500,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 22.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.com-unik.info/2018/01/06/albireo-pharmas-albo-buy-rating-reiterated-at-wedbush.html.
Albireo Pharma Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
What are top analysts saying about Albireo Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Albireo Pharma and related companies.